## Discovery of novel celastrol derivatives as Hsp90-Cdc37 interaction disruptors with antitumour activity

Na Li<sup>δ</sup>, Manyi Xu<sup>δ</sup>, Bing Wang, Zhixian Shi, Zihao Zhao, Yunqing Tang, Xinyue Wang, Jianbo Sun\*, and Li Chen\*

State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, People's Republic of China

## **Contents:**

1. Structural characterization of the compounds (<sup>1</sup>H NMR, <sup>13</sup>C NMR, ESI/HRMS spectrum of the final compounds **1-48**, **41-H** and **41-Bio**); 2. The synthetic route of compound **41-H**; 3. HPLC analysis of target compounds

1. Spectral data.



Fig. S3 ESI/HREMS spectrum of 1



Fig. S5. <sup>13</sup>C NMR spectrum of 2 (75 MHz in CDCl<sub>3</sub>)



Fig. S6 ESI/HRMS spectrum of 2



Fig. S9 ESI/HRMS spectrum of 3



Fig. S10 <sup>1</sup>H NMR spectrum of 4 (300 MHz in CDCl<sub>3</sub>)



Fig. S12 ESI/HRMS spectrum of 4



Fig. S13 <sup>1</sup>H NMR spectrum of **5** (300 MHz in CDCl<sub>3</sub>)



Fig. S15 ESI/HREMS spectrum of 5



Fig. S18 ESI/HREMS spectrum of 6



Fig. S19 <sup>1</sup>H NMR spectrum of **7** (300 MHz in CDCl<sub>3</sub>)



Fig. S21 ESI/HRMS spectrum of 7



Fig. S23 <sup>13</sup>C NMR spectrum of 8 (75 MHz in CDCl<sub>3</sub>)



Fig. S24 ESI/HRMS spectrum of 8



Fig. S25 <sup>1</sup>H NMR spectrum of **9** (300 MHz in CDCl<sub>3</sub>)



Fig. S27 ESI/HRMS spectrum of 9



Fig. S28 <sup>1</sup>H NMR spectrum of **10** (300 MHz in CDCl<sub>3</sub>)



Fig. S30 ESI/HRMS spectrum of 10



Fig. S31 <sup>1</sup>H NMR spectrum of **11** (300 MHz in CDCl<sub>3</sub>)







Fig. S34. <sup>1</sup>H NMR spectrum of **12** (300 MHz in CDCl<sub>3</sub>)



Fig. S35. <sup>13</sup>C NMR spectrum of **12** (75 MHz in CDCl<sub>3</sub>)



Fig. S36 ESI/HRMS spectrum of 12



Fig. S37 <sup>1</sup>H NMR spectrum of **13** (300 MHz in CDCl<sub>3</sub>)



Fig. S39 ESI/HRMS spectrum of 13



Fig. S40 <sup>1</sup>H NMR spectrum of **14** (300 MHz in CDCl<sub>3</sub>)



Fig. S42 ESI/HRMS spectrum of 14



Fig. S43 <sup>1</sup>H NMR spectrum of **15** (300 MHz in CDCl<sub>3</sub>)



Fig. S45 ESI/HRMS spectrum of 15



Fig. S46 <sup>1</sup>H NMR spectrum of **16** (300 MHz in CDCl<sub>3</sub>)



Fig. S48 ESI/HRMS spectrum of 16



Fig. S49 <sup>1</sup>H NMR spectrum of **17** (300 MHz in CDCl<sub>3</sub>)



Fig. S51 ESI/HRMS spectrum of 17



Fig. S52 <sup>1</sup>H NMR spectrum of **18** (300 MHz in CDCl<sub>3</sub>)







Fig. S55 <sup>1</sup>H NMR spectrum of **19** (300 MHz in CDCl<sub>3</sub>)



Fig. S57 ESI/HRMS spectrum of 19



Fig. S58 <sup>1</sup>H NMR spectrum of **20** (300 MHz in CDCl<sub>3</sub>)







Fig. S61 <sup>1</sup>H NMR spectrum of **21** (300 MHz in CDCl<sub>3</sub>)



Fig. S62 <sup>13</sup>C NMR spectrum of **21** (75 MHz in CDCl<sub>3</sub>)



Fig. S63 ESI/HRMS spectrum of 21



Fig. S64. <sup>1</sup>H NMR spectrum of **22** (300 MHz in CDCl<sub>3</sub>)



Fig. S65. <sup>13</sup>C NMR spectrum of **22** (75 MHz in CDCl<sub>3</sub>)



Fig. S66 ESI/HRMS spectrum of 22



Fig. S69 ESI/HRMS spectrum of 23



Fig. S70 <sup>1</sup>H NMR spectrum of **24** (300 MHz in CDCl<sub>3</sub>)



Fig. S72 ESI/HRMS spectrum of 24



Fig. S73  $^{1}$ H NMR spectrum of **25** (300 MHz in CDCl<sub>3</sub>)



Fig. S75 ESI/HRMS spectrum of 25



Fig. S76 <sup>1</sup>H NMR spectrum of **26** (300 MHz in CDCl<sub>3</sub>)



Fig. S78 ESI/HRMS spectrum of 26



Fig. S79 <sup>1</sup>H NMR spectrum of 27 (300 MHz in CDCl<sub>3</sub>)



Fig. S81 ESI/HRMS spectrum of 27



Fig. S82 <sup>1</sup>H NMR spectrum of **28** (300 MHz in CDCl<sub>3</sub>)



Fig. S84 ESI/HRMS spectrum of 28



Fig. S85 <sup>1</sup>H NMR spectrum of **29** (300 MHz in CDCl<sub>3</sub>)



Fig. S87 ESI/HRMS spectrum of 29



Fig. S88 <sup>1</sup>H NMR spectrum of **30** (300 MHz in CDCl<sub>3</sub>)



Fig. S90 ESI/HRMS spectrum of 30



Fig. S91 <sup>1</sup>H NMR spectrum of **31** (300 MHz in CDCl<sub>3</sub>)



Fig. S93 ESI/HRMS spectrum of 31



Fig. S94. <sup>1</sup>H NMR spectrum of **32** (300 MHz in CDCl<sub>3</sub>)



Fig. S95. <sup>13</sup>C NMR spectrum of **32** (75 MHz in CDCl<sub>3</sub>)



Fig. S96 ESI/HRMS spectrum of 32



Fig. S97 <sup>1</sup>H NMR spectrum of **33** (300 MHz in CDCl<sub>3</sub>)



Fig. S99 ESI/HRMS spectrum of 33



Fig. S100 <sup>1</sup>H NMR spectrum of **34** (300 MHz in CDCl<sub>3</sub>)



Fig. S102 ESI/HRMS spectrum of 34



Fig. S103 <sup>1</sup>H NMR spectrum of **35** (300 MHz in CDCl<sub>3</sub>)



Fig. S105 ESI/HRMS spectrum of 35



Fig. S106 <sup>1</sup>H NMR spectrum of **36** (300 MHz in CDCl<sub>3</sub>)



Fig. S108 ESI/HRMS spectrum of 36



Fig. S109 <sup>1</sup>H NMR spectrum of **37** (300 MHz in CDCl<sub>3</sub>)



Fig. S111 ESI/HRMS spectrum of 37



Fig. S112 <sup>1</sup>H NMR spectrum of **38** (300 MHz in CDCl<sub>3</sub>)







Fig. S115 <sup>1</sup>H NMR spectrum of **39** (300 MHz in CDCl<sub>3</sub>)



Fig. S117 ESI/HRMS spectrum of 39



Fig. S118 <sup>1</sup>H NMR spectrum of **40** (300 MHz in CDCl<sub>3</sub>)





Fig. S121 <sup>1</sup>H NMR spectrum of **41** (300 MHz in CDCl<sub>3</sub>)



Fig. S123 ESI/HRMS spectrum of 41



Fig. S124. <sup>1</sup>H NMR spectrum of **42** (300 MHz in CDCl<sub>3</sub>)



Fig. S125. <sup>13</sup>C NMR spectrum of **42** (75 MHz in CDCl<sub>3</sub>)



Fig. S126 ESI/HRMS spectrum of 42



Fig. S127 <sup>1</sup>H NMR spectrum of **43** (300 MHz in CDCl<sub>3</sub>)



Fig. S129 ESI/HRMS spectrum of 43



Fig. S130 <sup>1</sup>H NMR spectrum of 44 (300 MHz in CDCl<sub>3</sub>)



Fig. S132 ESI/HRMS spectrum of 44



Fig. S133  $^{1}$ H NMR spectrum of **45** (300 MHz in CDCl<sub>3</sub>)



Fig. S135 ESI/HRMS spectrum of 45



Fig. S136 <sup>1</sup>H NMR spectrum of **46** (300 MHz in CDCl<sub>3</sub>)



Fig. S138 ESI/HRMS spectrum of 46



Fig. S139 <sup>1</sup>H NMR spectrum of **47** (300 MHz in CDCl<sub>3</sub>)



Fig. S140<sup>13</sup>C NMR spectrum of **47** (75 MHz in CDCl<sub>3</sub>)







Fig. S142 <sup>1</sup>H NMR spectrum of **48** (300 MHz in CDCl<sub>3</sub>)





 Best
 V\*al
 D Source
 V\*al
 Formula
 V\*al
 Source
 V\*al
 Diff (abs. ppm)
 V\*al
 Diff (abs. ppm)

0.1 0.05



Fig. S146<sup>13</sup>C NMR spectrum of **41-Bio** (75 MHz in CDCl<sub>3</sub>)



Fig. S146<sup>13</sup>C NMR spectrum of **41-H** (75 MHz in CDCl<sub>3</sub>)





Fig. S149 <sup>1</sup>H NMR spectrum of **41** with DTT (75 MHz in DMSO- $d_6$ )

## 2. The synthetic route of compound **41-H**



Scheme S1. Reagents and Conditions: (a) sulfhydryl group, MeOH, rt, 15 min; (b)

Acetic anhydride, pyridine, rt, 12 h.

3. HPLC analysis of target compounds

1) HPLC analysis of compounds 1-15 (0.8 ml/min, 97% MeOH)





S54



3) HPLC analysis of compounds **41-H** (0.8 ml/min, 94% MeOH)

